DexCom, Inc. (NASDAQ:DXCM) Shares Purchased by Kayne Anderson Rudnick Investment Management LLC

Kayne Anderson Rudnick Investment Management LLC boosted its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 70.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,310 shares of the medical device company's stock after purchasing an additional 22,458 shares during the period. Kayne Anderson Rudnick Investment Management LLC's holdings in DexCom were worth $4,224,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of DexCom in the fourth quarter worth about $385,367,000. Congress Asset Management Co. boosted its stake in DexCom by 5,456.9% in the 4th quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD bought a new stake in shares of DexCom during the fourth quarter valued at approximately $96,507,000. Jennison Associates LLC raised its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock valued at $594,455,000 after buying an additional 710,858 shares during the last quarter. Finally, ExodusPoint Capital Management LP lifted its holdings in shares of DexCom by 197.6% in the fourth quarter. ExodusPoint Capital Management LP now owns 466,414 shares of the medical device company's stock worth $36,273,000 after buying an additional 309,714 shares in the last quarter. Institutional investors own 97.75% of the company's stock.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 105,009 shares of company stock worth $8,044,178 in the last quarter. Company insiders own 0.32% of the company's stock.

DexCom Price Performance

DXCM traded up $3.92 on Thursday, hitting $70.78. 3,922,797 shares of the company's stock were exchanged, compared to its average volume of 4,242,458. The firm has a 50-day moving average price of $73.46 and a 200-day moving average price of $76.61. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. The stock has a market cap of $27.75 billion, a price-to-earnings ratio of 49.50, a P/E/G ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $139.24.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wells Fargo & Company reiterated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup upped their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Cfra Research raised shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Morgan Stanley increased their target price on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Finally, Mizuho began coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 target price on the stock. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $99.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.